Neurocrine biosciences presents post hoc data analysis in congenital adrenal hyperplasia at espe 2023

San diego , sept. 21, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), today announced that it will present a new post hoc analysis of phase 2 data of the investigational drug crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency (21-ohd).
NBIX Ratings Summary
NBIX Quant Ranking